Microsoft word - final_chai arv ceiling price list may 2011 - english

The Clinton Health Access Initiative (CHAI) supports national governments to expand high-quality care and treatment to people living with HIV/AIDS. CHAI offers reduced prices for antiretrovirals (ARVs) to members of its Procurement Consortium. CHAI has agreements with eight manufacturers of ARV formulations, active pharmaceutical ingredients and/or pharmaceutical intermediates: Aurobindo Pharma, Cipla Ltd., Emcure Pharmaceuticals, Hetero Drugs, Matrix Laboratories, Micro Labs Ltd., Ranbaxy Laboratories and Strides Arcolabs. The ARVs included in CHAI’s pricing agreements are: abacavir (ABC), atazanavir (ATV), efavirenz (EFV), emtricitabine (FTC), lamivudine (3TC), lopinavir/ritonavir (LPV/r), nevirapine (NVP), ritonavir (RTV), stavudine (d4T), tenofovir (TDF) and zidovudine (AZT). Prices listed below are available to countries participating in the CHAI Procurement Consortium, which currently includes over 70 nations. These prices apply to procurements by national governments that are members of the CHAI Procurement Consortium, or organizations procuring on behalf of member governments, to support public care and treatment programs. Products should be purchased directly from partner suppliers or through procurement agents representing the aforementioned programs. For TDF products offered by suppliers under a voluntary license from Gilead, indicated pricing is available only to countries covered under the voluntary license. Please contact Neeraj Mohan at mneeraj@clintonhealthaccess.org with any questions related to this issue. Access to CHAI prices assumes prompt payment following the shipment of orders. Purchasers issuing requests for price quotes and/or tenders to which CHAI partner suppliers are invited to respond should reference membership in the CHAI Procurement Consortium, but requests and tenders need not be restricted to CHAI partner suppliers. CHAI ceiling prices represent the maximum levels at which indicated suppliers may price their products when selling or communicating price quotes to members of the CHAI Procurement Consortium. CHAI notes that there may be, in several cases, opportunities to obtain lower prices as a result of higher volumes, greater competition, and other market factors. We encourage Consortium members to seek and take advantage of such opportunities and to base treatment decisions on observed market prices, with ceiling prices indicating the upper bounds of treatment costs. Prices listed below are FCA Airport from the point of export. Annual treatment costs for pediatric formulations are determined based on the recommended daily dosing for a 10 kg child (unless a formulation is not recommended for a 10kg child, in which case the annual price is calculated based on dosing for an applicable weight band). CHAI is committed to the sustainable supply of high-quality ARVs, consistent with the specifications of dossiers approved by the World Health Organization (WHO), U.S. Food and Drug Administration (U.S. FDA), or a stringent regulatory authority (SRA) as defined by the International Conference on Harmonization (ICH). In the list below, footnotes specify the applicable quality assurance status for each formulation: (1) Approved by the WHO Prequalification Programme; (2) Approved by the U.S. FDA or other SRA; (3) Submitted to the WHO, U.S. FDA or other SRA for review and recommended for procurement by Expert Review Panel (ERP) of The Global Fund; (4) Submitted to the WHO, U.S. FDA or other SRA for review but not yet recommended by ERP. Clinton Health Access Initiative—Antiretroviral (ARV) Ceiling Price List AZT (300m g) + 3TC (150m g) + NVP (200m g) d4T (30m g) + 3TC (150m g) + NVP (200m g) *Abbott, the originator for the heat-stable formulation of RTV, has an access pricing policy of its own and has not joined CHAI’s ceiling price agreement. The company supplies the drug at a reduced price of $42 per person per year to its Category 1 countries, which includes countries in sub-Saharan Africa and all other Least Developed Countries. Thus, when the individual components are purchased separately from different suppliers, the TDF+3TC+ATV+RTV regimen is available at less than $410 per person per year. Clinton Health Access Initiative—Antiretroviral (ARV) Ceiling Price List * Price includes a measuring device such as a syringe, which was not included in the prior ceiling price list.

Source: http://www.hiv.com.cn/hiv/Files/CHAI%20ARV%20Ceiling%20Price%20List%20May%202011.pdf